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Disruption of cholinergic
neurotransmission, within a cognitive
challenge paradigm, is indicative of Aβ-
related cognitive impairment in preclinical
Alzheimer’s disease after a 27-month delay
interval
Jessica Alber1,2,3, Paul Maruff4,5, Cláudia Y. Santos1, Brian R. Ott3,6, Stephen P. Salloway3,6, Don C. Yoo7,
Richard B. Noto7, Louisa I. Thompson3, Danielle Goldfarb8, Edmund Arthur2, Alex Song9 and Peter J. Snyder1,6*
Abstract
Background: Abnormal beta-amyloid (Aβ) is associated with deleterious changes in central cholinergic tone in the
very early stages of Alzheimer’s disease (AD), which may be unmasked by a cholinergic antagonist (J Prev
Alzheimers Dis 1:1–4, 2017). Previously, we established the scopolamine challenge test (SCT) as a “cognitive stress
test” screening measure to identify individuals at risk for AD (Alzheimer’s & Dementia 10(2):262–7, 2014) (Neurobiol.
Aging 36(10):2709-15, 2015). Here we aim to demonstrate the potential of the SCT as an indicator of cognitive
change and neocortical amyloid aggregation after a 27-month follow-up interval.
Methods: Older adults (N = 63, aged 55–75 years) with self-reported memory difficulties and first-degree family
history of AD completed the SCT and PET amyloid imaging at baseline and were then seen for cognitive testing at
9, 18, and 27 months post-baseline. Repeat PET amyloid imaging was completed at the time of the 27-month
exam.
Results: Significant differences in both cognitive performance and in Aβ neocortical burden were observed
between participants who either failed vs. passed the SCT at baseline, after a 27-month follow-up period.
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Conclusions: Cognitive response to the SCT (Alzheimer’s & Dementia 10(2):262–7, 2014) at baseline is related to
cognitive change and PET amyloid imaging results, over the course of 27 months, in preclinical AD. The SCT may be
a clinically useful screening tool to identify individuals who are more likely to both have positive evidence of
amyloidosis on PET imaging and to show measurable cognitive decline over several years.
Keywords: Alzheimer disease, Preclinical Alzheimer’s disease, Early detection, Cholinergic, Cognition, Biomarkers,
Early diagnosis, Anticholinergic drugs, Scopolamine, Beta-amyloid protein
Background
To best slow the neuropathologic cascade and deterior-
ation of cognitive functions due to Alzheimer’s disease
(AD), neuroprotective treatments will likely be most effi-
cacious if administered during the preclinical stages of
the disease [1, 2]. However, reliably identifying healthy
individuals at high risk of developing AD currently re-
quires biomarkers that are either invasive, expensive,
and/or labor intensive to obtain [3–5]. Complex and ex-
pensive diagnostic procedures, such as imaging of neo-
cortical amyloid and tau protein aggregation by positron
emission tomography (PET), are limited to patients and
facilities with access to the necessary resources and ex-
pertise [6, 7]. There remains a need for low-cost, minim-
ally invasive screening tools for AD risk that may be
readily administered by point-of-care providers [8].
We have previously proposed a cognitive stress test
with sensitivity to detect the earliest neuropathologic
changes in the basal forebrain cholinergic system that
herald incipient AD [9]. The test involves the adminis-
tration of a micro-dose of the muscarinic anticholinergic
agent, scopolamine hydrobromide (0.2 mg, subcutaneous
injection [s.c.]) prior to completion of a well-validated
cognitive test previously shown to be sensitive to the
manipulation of cholinergic tone [10], in order to un-
mask prodromal cognitive deficits indicative of choliner-
gic system changes and cortical beta-amyloid (Aβ)
aggregation in older adults [1]. We explored the clinical
utility of this scopolamine challenge test (SCT) in a lon-
gitudinal study of 63 mid-life adults (mean age = 62.79
years) with two known risk factors for AD. All partici-
pants completed the SCT at baseline, as well as amyloid
PET imaging and neuropsychological assessments at
baseline and at a 27-month follow-up exam. We have
previously reported the baseline exam results from this
study, which suggest that the use the SCT may be an ef-
fective way of identifying cognitively normal (CN) adults
who demonstrate abnormal neocortical Aβ protein ag-
gregation on PET imaging and are therefore likely in the
preclinical stage of AD [11].
In this brief report, we present the 27-month follow-
up results from the participants in this same study, with
the aim of discerning whether the SCT may be a reliable
indicator of continued risk for disease progression.
Methods
Participants
Sixty-three adults aged between 55 and 75 years, with a
self-reported first-degree family history of AD and sub-
jective memory complaints, were recruited from two
memory disorder clinics in Rhode Island and broad ad-
vertising to the community. All participants underwent a
detailed medical screening interview to exclude those
who were diagnosed with MCI or AD, had a history of
neurological or psychiatric disorder, were afflicted by
any significant systemic illness or unstable medical con-
dition, or used medications known to affect cognition.
Inclusion criteria were a Mini-Mental State Examination
(MMSE) total score > 27 and performance within normal
limits on a battery of cognitive tests with demonstrated
sensitivity to preclinical and prodromal AD (see Table 1).
Participants were separated into high- (N = 15) versus
low-Aβ (N = 48) groups on a post hoc basis, but the
study team was kept blind to PET amyloid status until
all baseline exams were completed and the results were
reported by Lim et al. [11]. Table 1 summarizes the
demographic and clinical characteristics of the study
sample. The study was approved by and complied with
the regulations of Rhode Island Hospital’s Institutional
Review Board. All participants provided written in-
formed consent.
Procedure
All participants completed the SCT at baseline, as
described by Lim et al. [11]. Briefly, each subject com-
pleted a practice on the cognitive test (the Groton Maze
Learning Test [GMLT]; www.cogstate.com), followed by
a larger battery of cognitive tests (see Table 1) and a
pre-dosing baseline GMLT test. Subjects then received
an injection of scopolamine (0.2 mg s.c.). Following con-
firmation that vital signs had returned to pre-dose levels,
the GMLT was re-administered at 1, 3, 5, 7, and 8 h post
dosing. All subjects who failed to return to their own
baseline performance level on the GMLT by five (5)
hours post dosing were considered to have “failed” the
SCT and thus were considered at increased risk for pre-
clinical AD [11]. Participants also completed a cheek
swab for apolipoprotein E (APOE) genotyping as an in-
dicator of genetic AD risk at baseline, and florbetapir
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amyloid PET imaging at the baseline and 27-month
exams, along with repeat cognitive assessments at 9, 18,
and 27 months. Refer to the procedure as described by
Lim et al. [11] for more details.
Measures
All cognitive and psychological measures have been de-
scribed by Lim et al. [11]. The neuropsychological tests
assessed verbal memory (International Shopping List
Test [ISLT; [12]), visual memory (Cogstate One Card
Learning [OCL; [13] task), and working memory (Cog-
state One Back [OBK; [13] task) (see Table 1). The
Mini-Mental Status Exam (MMSE) was used to assess
general cognitive function, and participants’ mood was
measured using the 15-item Geriatric Depression Scale
(GDS [14]) and the Depression, Anxiety and Stress Scale
(DASS [15]). Subjective memory impairment was deter-
mined using the Memory Complaint Questionnaire
(MAC-Q [16]). All measures were administered by
trained staff supervised by a neuropsychologist.
As noted above, the GMLT was used in the SCT to
detect/measure cholinergic-mediated disruptions in cog-
nitive function following scopolamine administration.
The GMLT, created by one of the authors (P.J.S.), is a
computerized neuropsychological test of spatial working
memory, learning efficiency, and error monitoring. The
design and task requirements for the GMLT have been
previously well described [10, 17]. Briefly, the task re-
quires the participant to find a hidden pathway through
a grid from the top left corner to a flag in the bottom
right corner. The trial ends once the participant reaches
the bottom right corner of the grid. Each participant
completes five successive learning trials. The three main
outcome measures of the GMLT are (1) mean correct
moves per second across the five learning trials (MPS);
(2) total number of errors made across the five learning
trials (TER); and (3) total number of rule break errors
made across the same five learning trials (RER). These
three measures were standardized against the group
baseline mean and standard deviation, and then averaged
to form a GMLT composite.
Aβ PET imaging
A 370MBq (10 mCi +/− 10%) bolus injection of F-
florbetapir [18] was administered intravenously at base-
line and once again at 27 months. Approximately 50 min
Table 1 Demographic and clinical characteristics at baseline exam, for the full sample and for the two subgroups (those who either
failed or passed the scopolamine challenge test (SCT) at their baseline exams)
Main outcome Full sample (n = 58) SCT fail (n = 28) SCT pass (n = 30)
N (%) N (%) N (%) p Cohen’s d
Sex No. of female 38 (60%) 20 (71%) 18 (60%) .296 –
APOE No. of ε4 carriers 30 (48%) 17 (58%) 13 (43%) .559 –
Mean (SD) Mean (SD) Mean (SD) p
Age No. of years 63.06 (5.42) 63.93 (6.31) 62.44 (5.04) .349 0.28
Education No. of years 17.21 (2.77) 17.47 (3.46) 17.14 (2.55) .689 0.12
SUVr (neocortex) Standardized uptake value ratio 1.023 (0.19) 1.10 (0.24) 0.95 (0.09) .000 2.47
SUVr (anterior cingulate) Standardized uptake value ratio 1.064 (0.22) 1.197 (0.27) 0.984 (0.10) .000 2.95
GDS Total score 1.86 (2.16) 1.60 (1.45) 1.94 (2.35) .602 − 0.16
DASS Depression Subscale Total Depression Subscale Score 3.56 (6.70) 2.60 (2.59) 3.87 (7.56) .526 − 0.19
DASS Anxiety Subscale Total Anxiety Subscale Score 2.73 (4.53) 2.40 (3.58) 2.83 (4.83) .752 − 0.09
DASS Stress Subscale Total Stress Subscale Score 6.73 (6.77) 6.67 (4.55) 6.74 (7.38) .969 − 0.01
MAC-Q Total score 21.80 (3.57) 21.35 (3.94) 21.28 (3.27) .501 0.15
Body mass index Body mass index 26.69 (5.50) 28.66 (7.95) 26.07 (4.41) .113 0.48
MMSE Total score 29.05 (1.02) 28.93 (1.16) 29.08 (0.99) .624 − 0.15
GMLT Moves/Second (MPS) Total correct moves/second 0.81 (0.20) 0.78 (0.20) 0.81 (0.19) .573 − 0.17
GMLT Total Errors (TER) Total no. of errors 55.60 (14.38) 53.21 (16.21) 52.79 (14.80) .430 − 0.22
GMLT Composite Standardized z-score − 0.02 (0.81) − 0.08 (0.89) − 0.01 (0.79) .764 − 0.09
ISLT Total Recall Total words recalled (three learning trials) 25.62 (4.20) 24.04 (4.41) 27.85 (4.16) .368 − 0.28
One Card Learning task Accuracy of performance 1.01 (0.10) 1.05 (0.03) 1.10 (0.10) .085 − 0.40
One Back task Accuracy of performance 1.45 (0.11) 1.40 (0.14) 1.46 (0.10) .063 − 0.54
*Note: APOE apolipoprotein, SUVr standardized uptake value ratio, GDS Geriatric Depression Scale, DASS Depression, Anxiety, and Stress Scale, MAC-Q Memory
Complaints Questionnaire, MMSE Mini-Mental State Examination, GMLT Groton Maze Learning Task, ISLT International Shopping List Test; bolded values are
significant at the p < .001 level
Alber et al. Alzheimer's Research & Therapy           (2020) 12:31 Page 3 of 9
post-injection, a 20-min PET scan was performed with
head CT scan for attenuation correction purposes. PET
standardized uptake value (SUV) data were summed and
normalized to the whole cerebellum SUV, resulting in a
region-to-cerebellum ratio termed SUV ratio (SUVr). An
SUVr threshold of ≥ 1.1 was used to discriminate be-
tween Aβ− and Aβ+; however, rather than using an
average of recommended cortical areas [19], we defined
Aβ+ as individuals with anterior cingulate (AC) SUVr ≥
1.1. This definition was chosen for the following reasons:
(1) we would not expect widespread neocortical amyl-
oidosis in the very early preclinical stage of AD [20] in
this sample, given the relatively young age of participants
(i.e., on average 10 years younger than is typically the
case for clinical trials cohorts [21, 22]), (2) the relation-
ship between the AC and early changes in cholinergic
tone [23, 24], and (3) emerging research suggests that in-
creased Aβ burden, in the AC specifically, is highly
related to memory changes in early AD [25, 26]. Table 1
also provides between-group differences on the estab-
lished measure of total neocortical SUVr (averaged over
six regions of interest [19]). For all cases, Aβ positivity
was confirmed by consensus over-read by two board-
certified radiologists who were also board-certified in
Nuclear Medicine.
Data analysis
All analyses were performed using JMP statistical soft-
ware, version 12.0.1 (SAS Institute). The delayed free re-
call portion of the ISLT (a 12-item word-list learning test)
was the key cognitive outcome measure for determining
the clinical utility of the SCT to predict relative cognitive
impairments at 27months post-screening. This measure
was chosen to avoid unnecessary and potentially mislead-
ing multiple comparisons, and because there is now clear
evidence in the literature that verbal episodic memory is
one of the earliest and most reliable domains to show AD-
associated cognitive change [12, 27]. All subjects were sep-
arated into those who failed vs. passed the SCT at baseline
(following [11]), and these groups were compared with
two-way ANCOVA analyses (with age and APOE status
entered as covariates) to determine (1) any main effects
for ISLT delayed recall performance and (2) any amyloid
PET imaging differences, at the 27-month outcome exam.
Next, a generalized estimating equation (GEE; [28])
was used to compare within-subject changes over the
four exam time points, with respect to performance on
both the ISLT and the GMLT between patients who
passed and patients who failed the SCT. These differen-
tial changes were tested using a set of orthogonal linear
contrasts: a 7-coefficient test for differences in linear
trends across the four visit time points. GEEs are gener-
alized linear models wherein the within-subject nesting
is accounted for in the residual error of the model [28].
The selection of distribution for our models was guided
based on the theory that simple counts ought to be Pois-
son distributed, and confirmed by model residuals. A
compound symmetry variance-covariance structure was
used with classical sandwich estimation to adjust for any
misspecification [29]. To test the effect of SCT pass/fail
on change in amyloid burden over time, we computed
the absolute difference between baseline ACC SUVr and
the 27-month ACC SUVr. We conducted an independ-
ent samples t-test for the SCT pass vs. fail group, with
the absolute difference in the ACC SUVr (change in
amyloid burden) as the dependent variable. Cohen’s d
was used as the effect size measure. To determine
whether SCT fail/Aβ PET+ subjects decline in episodic
memory (measured using ISLT delayed recall score)
compared to SCT fail/Aβ− subjects, we conducted a
mixed model ANCOVA, co-varying for age. P values <
0.05 were considered statistically significant for all
analyses.
Receiver operating characteristic (ROC) analysis of SCT for
amyloid PET status at baseline
The SCT was only administered at baseline and not at
the 27-month follow-up visit. However, since the amyl-
oid burden and absolute change in amyloid burden
(ACC SUVr and absolute change in ACC SUVr) were
consistently higher in the SCT fail group than the SCT
pass group at both baseline and 27months, we assumed
that an ROC analysis of SCT for Aβ PET status at base-
line would be similar to that at 27 months follow-up.
Therefore, to test the sensitivity and specificity of SCT
for amyloid PET status, we first found the proportion of
Aβ+ participants in the SCT fail/pass group at baseline
using a chi-square test with Yate’s correction. Next, an
ROC analysis was conducted, examining SCT sensitivity
and specificity for detection of amyloid burden on Aβ
PET. The highest Youden index was used to set our cut-
off and the corresponding sensitivity and specificity
values. While SCT outcomes were dichotomized for
other analyses, continuous GMLT composite scores [11]
during the SCT were used for the ROC analysis.
Results
In total, 58 of 63 participants completed all four exams
over the 27-month study period (92% retention rate).
Four subjects were lost to follow-up either because of re-
location of their homes or loss of interest. One subject
was diagnosed with progressive supranuclear palsy after
the 18-month visit and was excluded from the study.
The amount of neocortical Aβ aggregation and APOE
genotype were unknown at the time of assessment and
were not used to determine enrollment. Although Aβ
status and APOE genotyping were conducted as a part
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of the study protocol, researchers remained blinded to
these results throughout testing.
Of the 58 participants that completed all exam visits,
there were 38 females, 11 of whom were Aβ+ on PET
imaging. Four males were Aβ+ on PET imaging. There
were no significant differences between SCT fail and
SCT pass groups with respect to sex (p = 0.296). Like-
wise, there were no group differences in the proportion
of individuals with the APOE ε4 genetic risk marker for
AD. The mean age for the total sample was 63 years old
and this sample had an average of 17 years of education.
All relevant demographic information, for the entire
sample, and broken down by SCT pass and SCT fail
groups, is provided in Table 1. There were no group dif-
ferences with respect to body mass index, subjective
memory complaints, and cognitive performance at base-
line exam (on any of the tests described above). By def-
inition, both groups significantly differed with respect to
neocortical amyloid aggregation as measured via PET
imaging (p < .001).
With respect to genetic risk for AD, 17 of 28 individ-
uals (58%) in the SCT fail group (those who failed the
SCT at the time of their baseline exams) had at least one
copy of the APOE ε4 allele, whereas 13 of 30 individuals
(43%) in the SCT pass group (those who passed the SCT
at the time of their baseline exams) had at least one copy
of the APOE ε4 allele. Hence, more subjects in the SCT
fail group presented with this additional risk factor for
AD, but due to small sample sizes, we were not able to
further evaluate the specific effect of APOE genetic risk
on the relationship between SCT performance at base-
line and cognitive performance 27 months later. We did,
however, co-vary for APOE status in the analyses de-
scribed below.
Relationship between pass/fail on SCT at baseline and
florbetapir PET Aβ binding 27months later
Consistent with our initial findings at the time of the
baseline PET scan reported previously [11], at 27 months
follow-up, subjects who failed the SCT (n = 28) contin-
ued to show significantly greater amyloid binding in the
ACC (mean SUVr = 1.197) compared to those who
passed the SCT (n = 30) at baseline (mean SUVr = 0.984)
after controlling for main effects of age (df = 1, MS =
24.87, F = 8.734, p = 0.0046), with a moderate-to-large
effect size difference between groups (Cohen’s d = 0.75).
There was no significant difference between the SCT
pass and SCT fail groups in age (p = .81). The SCT fail
group (0.106 ± 0.086) had significantly greater amyloid
accumulation over 27 months in the ACC (measured
using mean change in Aβ PET SUVr between baseline
and 27 month follow-up) than the SCT pass group
(0.064 ± 0.055), t(54) = 2.21, p = 0.031, with a moderate
effect size (Cohen’s d = 0.58).
Relationship between pass/fail on SCT at baseline and
episodic verbal memory performance 27months later
After controlling for age and APOE status, no group dif-
ferences were found in performance on our chosen
measure of episodic memory (ISLT delayed recall), at
the time of the initial baseline exam, between those who
failed (n = 31) versus passed (n = 32) the SCT (p = 0.93).
However, at the time of the last study visit 27 months
later, those who failed the SCT at the baseline exam per-
formed significantly worse on the ISLT delayed recall
test than those who passed the SCT at baseline (df = 1,
MS = 1799.95, F = 5.337, p = 0.025), with a moderate ef-
fect size difference between groups (Cohen’s d = 0.58).
Visual inspection of the performance of each group
over the course of all four study exams (i.e., at baseline,
9, 18, and 27 months post-baseline) suggested that the
group that passed the SCT at baseline benefited from
modest practice effects on the ISLT delayed recall task,
over the course of the study, whereas those who failed
the SCT at baseline did not show evidence of benefiting
from continued practice on the test over the study
period (see Fig. 1). The GEE model (described above)
confirmed this observation (see Table 2) for the ISLT
delayed recall.
Although the GEE analysis revealed a group difference
in performance on the GMLT over the four study visits,
it was only the ISLT delayed recall measure that
remained significant after adjusting for non-normal dis-
tributions (Table 2).
Decline on ISLT between SCT fail/Aβ+ vs. SCT fail/Aβ−
group
There was significantly worse ISLT delayed recall task
performance at all time points for the SCT fail/Aβ PET+
group compared to the SCT fail/Aβ PET− group (df = 1,
MS = 105.67, F = 9.02, p = 0.006), with a large effect size
(Cohen’s d = 1.12) (See Fig. 2).
ROC analysis results of SCT scores for amyloid PET status
at baseline
The proportion of the SCT fail group (0.45) who were
Aβ+ was significantly greater than that of the SCT pass
group (0.03), X(1) = 13.11, p = .000294. The area under
the curve (AUC) of SCT scores for amyloid PET status
is 0.867 (CI = 0.775–0.959). Taking the highest Youden
index, an SCT score less than or equal − 0.068 indicated
the participant was likely amyloid PET positive with a
sensitivity of 1.00 and a specificity of 0.673. Thus, the
SCT scores were highly sensitive for amyloid PET status
at baseline.
Discussion
In a group of cognitively normal, healthy, mid-life adults
with subjective memory complaints and first-degree
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family history of AD who all were neurologically within
normal limits on a battery of cognitive tests at baseline,
we showed that an initial micro-dose scopolamine chal-
lenge test (SCT) may both reveal masked prodromal
cholinergic defects [11], as well as identify those who
show increased neocortical amyloid aggregation and
continued cognitive changes over a 27-month follow-up
period.
The results of this study support the hypothesis that
baseline performance the SCT is related to cognitive
changes 27 months later, in association with preclin-
ical AD. The results also show that baseline perform-
ance on the SCT is related to PET amyloid imaging
results at 27 months, in preclinical AD. Moreover,
those who failed the SCT at baseline had greater Aβ
accumulation in the ACC over a 27-month period
than those who passed the SCT at baseline, indicating
that the SCT could be sensitive to amyloid accumula-
tion over time in the earliest stages of the AD patho-
physiologic cascade. At the terminus of the study,
participants who failed the SCT at baseline also per-
formed significantly worse on an episodic memory
test.
Taken together, these results mirror larger cohort
studies indicating that Aβ+ preclinical AD patients show
a greater longitudinal rate of decline in episodic memory
than Aβ− CN older adults [30–33], lending credence to
the validity of the SCT as a viable screening tool for
preclinical AD. The fact that SCT-related longitudinal
cognitive changes were more pronounced in CN, Aβ+
participants could indicate that amyloidosis and cholin-
ergic neurotransmission are either directly or indirectly
related in the earliest AD disease stages, and that this
relationship persists over at least 27 months.
Fig. 1 Performance on the International Shopping List (ISLT) Delayed Recall Task, by participants who either failed the scopolamine challenge test
(SCT) at baseline (N = 28, at end of study) vs. those who passed the SCT at baseline (N = 30, at end of study), modeled over all four study visits.
Dark lines indicate group mean scores at each visit, with SE bars provided. Both between- and within-subject variation is represented in each
group, by displaying individual subject change over time, with each case yoked to the group baseline mean score
Table 2 Differences in ISLT and GMLT performance between subjects who failed (N = 28) vs. passed (N = 30) the SCT at baseline,
modeled by generalized estimating equation (GEE) over the baseline, 9-, 18-, and 27-month examinations
Task p values for comparison of linear trends across adjusted p values and four (4) time points Method of adjustment
ISLT—Immediate Recall 0.0397* 0.0652 (binomial)
ISLT—Delayed Recall 0.0066* 0.0132* (binomial)
GMLT—Moves/Second 0.0328 0.0656 (log normal)
GMLT—Total Errors 0.0254 0.0507 (log normal)
GMLT—Delayed Recall
Total errors 0.2469 0.2469 (log normal)
*p < 0.05
ISLT International Shopping List Test, GMLT Groton Maze Learning Test
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The absence of cognitive decline in cognitively normal
older adults over time in this study is expected and has
been shown in larger cohort studies (cf. [33]). However,
participants who passed the SCT at baseline showed reli-
able practice effects on the ISLT over the 27-month
period, whereas those who failed the SCT at baseline did
not demonstrate expected practice effects. That is, those
who failed the SCT generally did not show reliable
improvements in cognitive performance as a result of
benefitting from repeated exposures to the cognitive test.
The absence of this effect within the SCT− group corre-
sponds to literature demonstrating a lack of practice
effects in episodic memory tasks in those with preclinical
AD [34, 35]. Our data support the hypothesis that lack
of practice effects on an episodic memory test could
indicate a preclinical AD state in cognitively normal
older adults.
Looking more closely at the SCT fail group, participants
who were Aβ+ at baseline performed consistently worse
than those who failed the SCT and were Aβ− at all time
points on an episodic memory test (see Fig. 2), supporting
other studies that have shown a reduced episodic memory
performance in Aβ+ vs. Aβ− over time [32].
Notably, there were a few individuals in this study who
failed the SCT at baseline, but remained Aβ− after a 27-
month follow-up period. Importantly, our analyses found
that regardless of Aβ PET status, participants who failed
the SCT experienced increased cognitive decline over
the same follow-up period. These individuals could be
experiencing cholinergic disturbance due to non-AD
related pathology. Alternatively, cholinergic disturbance
is one of the earliest symptoms in the AD pathophysio-
logic cascade, and these individuals could be particularly
susceptible to cholinergic disturbance due to epigenetic,
demographic, and other relevant risk factors [36–39].
We suspect, with longer follow-up, these individuals
may convert to Aβ+, although further research is
required to define the pathophysiologic relationship
between amyloid and cholinergic dysfunction in the
earliest stages of AD.
As a screening approach, the SCT also has the poten-
tial to improve current statistics on screening failure rate
for AD prevention trials through increased efficiency.
Our ROC analysis at baseline showed that the SCT was
a highly sensitive predictor of Aβ PET positivity. A
specificity value of 0.673 indicates that the SCT alone
may not be able to rule out amyloid pathology in cogni-
tively normal older adults. However, future analyses
could examine the specificity of SCT in combination
with other factors related to Aβ pathology in preclinical
AD, such as episodic memory, family history, and APOE
genotype, for detection of Aβ pathology. Presently,
screening failure rate in Alzheimer’s prevention clinical
trials is estimated at up to 75% [40] and the use of amyl-
oid PET scans as a risk assessment is invasive, and often
cost prohibitive. The SCT, due to its relative simplicity
and limited resource requirements, has the potential to
be used by point-of-care clinicians when PET imaging is
not widely available. This will be critical once preventa-
tive therapies for AD become available. Using SCT,
those at risk who can potentially benefit from longitu-
dinal administration of preventative therapies could po-
tentially be quickly and efficiently identified.
This study has several limitations for consideration.
First, the follow-up period was only 27 months, which
limits the capacity to track the trajectory of cognitive
decline over time, especially in a cognitively normal
population. Second, our sample size was small, specific-
ally the sample size of Aβ+ CN participants (n = 15), and
neocortical amyloidosis does not change dramatically
over 27 months, which limits the range of SUVr change
over time in our analyses. Also, SCT was only done at
baseline and not at the 27-month follow-up visit, which
limits our extrapolation of the sensitivity and specificity
of SCT scores for Aβ PET status to our baseline data.
Future work is required to examine the sensitivity/speci-
ficity of the SCT for future conversion to positive Aβ
PET in cognitively normal older adults. Despite this
limitation, our data show that CN participants who
failed the SCT had increased amyloidosis at baseline that
persisted at least 27 months. Third, our sample was
primarily Caucasian and highly educated, with no
comorbid neurological or psychiatric disorders, which
may not be representative of the general population. In
the future, we plan to replicate this study with a larger,
more representative sample and use a longer follow-up
period to examine longitudinal cognitive changes. More-
over, our sample was relatively young. In order to valid-
ate the SCT as a screening tool, further data collection
in a cohort of older adults in the age range where risk
Fig. 2 Profile plot showing a significantly reduced performance on
the International Shopping List Test (ISLT) Delayed Recall Task for
the SCT fail/Aβ+ group compared to the SCT fail/Aβ− group over a
27-month follow-up period. Error bars represent standard deviation
from the mean
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for AD is substantially increased is required. Another
possible limitation is the length of time required to ad-
minister the SCT (5 h). Although this adds to the length
of the screening procedure, Aβ PET takes 3–3.5 h to
complete, and centers without the staff, equipment, or
resources to use this test could eventually use the SCT,
which is minimally invasive and considerably more cost
efficient. Additionally, future research should examine
the use of the SCT as a screening measure in regions
where Aβ PET imaging is not readily available. Finally,
testing this screening measure in the autosomal domin-
ant AD population presents a unique opportunity to
examine the pathophysiological interactions between
cholinergic neurotransmission and amyloidosis in the
earliest stages of the disease, and could provide valuable
insight into the early mechanistic relationships between
these two processes that are relevant for the develop-
ment of preventative therapies.
Conclusions
SCT is a reliable indicator of continued risk for AD
progression and may provide a low-cost, minimally
invasive screening method to identify persons at high
risk for cortical amyloid aggregation and cognitive de-
cline. Subjects who failed the SCT continued to show
significantly greater amyloid binding in the AC after
27 months compared to subjects who passed the SCT
(p = 0.0046), along with increased rate of amyloid ac-
cumulation over the 27-month period as shown on
Aβ PET. Besides, those who failed the SCT performed
significantly worse on an episodic memory cognitive
test (ISLT delayed recall test) than those who passed
the SCT at baseline (p = 0.025). Only those who
passed SCT show evidence of benefiting from contin-
ued practice on the test over the study period. Future
research should examine the use of the SCT as a
screening measure in regions where Aβ PET imaging
is not readily available. Exploration of the SCT as a
screening measure in an autosomal dominant AD
population may allow a unique opportunity to exam-
ine the pathophysiological interactions between cho-
linergic neurotransmission and amyloidosis in the
earliest stages of the disease.
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